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Abstract.  Primary  pancreatic  lymphoma  (PPL)  is  an  extremely  rare  disease  which  occurs  in 
pancreas, accounts for less than 1% of extra
pancreatic masses. We report the case of PPL in a 15 year
Diabetes of the Young type 3 (MODY3) diagnosed at the age of 1 year.
Introduction. Diabetes Mellitus has been reported as 
presenting symptom associated to Primary Pancreatic 
Lymphoma (PPL), related to the lymphoma infiltration 
of  pancreatic  tissue  and  the  following  exocrine  and 
endocrine  insufficiency.  Nevertheless,  the  onset  of 
isolated PPL in a patient suffering from a monogenic 
type  of  diabetes  has  not  been  previously  reported.  
Here we describe the case of a 15 years old young man 
with a pediatric diagnosis of Type I Diabetes Mellitus 
made at 1 year of age and later redefined as Matur
onset  Diabetes  of  the  young  type  3  (MODY3) 
according to immunologic and molecular assays, who 
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Primary  pancreatic  lymphoma  (PPL)  is  an  extremely  rare  disease  which  occurs  in 
pancreas, accounts for less than 1% of extra-nodal malignant lymphomas and 0,5% of cases of 
pancreatic masses. We report the case of PPL in a 15 year-old boy suffering from Matu
Diabetes of the Young type 3 (MODY3) diagnosed at the age of 1 year.  
Diabetes Mellitus has been reported as 
presenting symptom associated to Primary Pancreatic 
Lymphoma (PPL), related to the lymphoma infiltration 
of  pancreatic  tissue  and  the  following  exocrine  and 
endocrine  insufficiency.  Nevertheless,  the  onset  of 
PPL in a patient suffering from a monogenic 
type  of  diabetes  has  not  been  previously  reported.  
Here we describe the case of a 15 years old young man 
with a pediatric diagnosis of Type I Diabetes Mellitus 
made at 1 year of age and later redefined as Maturity 
onset  Diabetes  of  the  young  type  3  (MODY3) 
according to immunologic and molecular assays, who 
developed a PPL, a rare form of extranodal lymphoma 
more commonly diagnosed in advanced age.
a monogenic form of non-insulin
related to heterozygous germline mutation in HNF1A, 
has  been  considered  a  precancerous  condition, 
predisposing the different type of tumor. We think that 
the uncommon association of these two rare diseases is 
worth being reported.
Case Report. A 15-year old boy with a diagnosis of 
Diabetes Mellitus made from the age of 1 year, was 
admitted to the hospital reporting one
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Primary  pancreatic  lymphoma  (PPL)  is  an  extremely  rare  disease  which  occurs  in 
nodal malignant lymphomas and 0,5% of cases of 
old boy suffering from Maturity Onset 
developed a PPL, a rare form of extranodal lymphoma 
more commonly diagnosed in advanced age.
1 MODY3, 
insulin-dependent diabetes, 
related to heterozygous germline mutation in HNF1A, 
has  been  considered  a  precancerous  condition, 
predisposing the different type of tumor. We think that 
the uncommon association of these two rare diseases is 
year old boy with a diagnosis of 
Diabetes Mellitus made from the age of 1 year, was 
admitted to the hospital reporting one-month history of Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
jaundice.  He  presented  in  good  general  conditions, 
without any abdominal pain or B symptoms. Physical 
examination  revealed  skin  and  scleral  jaundice,  no 
organomegaly or peripheral lymphoadenopathy.
Blood  chemical  assays  showed  abnormal  liver 
function  tests  (GOT  73  UI/l,  GPT  144  UI/l,  serum 
alkaline  phosphatase  583  UI/l,  total  bilirubin  10,61 
mg/dl),  elevated  LDH  (504  UI/l)  and  beta2-
microglobulin  (3,2  mg/l).  WBC  count  and  platelets 
count  were  within  the  normal  range,  whereas  a 
normochromic  normocytic  anemia  was  detected 
(hemoglobin 10.6 g/dl). Serologic tests for HIV, HBV, 
HCV,  CMV,  EBV  and  Toxoplasma  were  negative.
Tumor  markers  included  CA19-9,  alpha-Fetoprotein 
and CEA were within normal ranges.
The CT abdominal scan showed a 4.0x3.2 cm low 
density  tumor  in  the  head  of  the  pancreas, 
heterogeneously  enhancing  and  obstructing  the 
common bile duct and the main pancreatic duct, many 
centimetric  peripancreatic  lymphadenopathies  and 
normal  spleen  and  liver.  The  patient  underwent 
Endoscopic  Retrograde  Cholangiopancreatography 
(ERCP)  and  a  stent  was placed  in  the  common  bile 
duct, obtaining the improvement of the jaundice. An 
endoscopic  ultrasound  (EUS)  guided  fine  needle 
aspiration  biopsy  (FNAB)  was  performed  and 
cytological examination revealed a massive infiltration 
by CD20 and LCA expressing lymphocytes.
The patient was then admitted to our Department of 
Hematology  where  he  completed  a  CT  scan  of  the 
head,  neck  and  chest,  showing  no  significant 
lymphadenopathies  or  parenchymal  lesions.  Bone 
marrow  aspiration  and  trephine  biopsy  revealed  no 
lymphoma  involvement.  Fluorine-18-Fluoro-deoxy-
glucose  positron  emission  tomography/computed 
tomography (
18F-FDG PET/CT) was performed using a 
hybrid  scanner  (Philips  Gemini  GXL)  and  showed 
increased glucose metabolism in the known lesion in 
the head of pancreas (Figure 1A), as well as in one 
more smaller area in the tail of pancreas and in one 
lymph  node  in  the  hepato-gastric  ligament  (Figure 
1B).  
To  have  a  more  detailed  histopathological 
diagnosis,  an  EUS-guided  Trucut  biopsy  was 
performed  and  the  pathology  report  documented  the 
complete substitution of pancreatic parenchyma by  a 
large  blasts  proliferation,  expressing  CD20,  PAX-5, 
CD10, BCL-6 and MIB-1 proliferative index of 70%, 
suggestive  of  Diffuse  Large  B  Cell  Lymphoma 
(DLBCL) of the pancreas (Figure 2). Considering the 
extensive  and  multifocal  pancreatic  involvement 
associated  with  the  involvement  of  peripancreatic 
lymph  nodes,  the  final  diagnosis  was  primary 
pancreatic  DLBCL,  stage  IVEA,  age-adjusted 
International  Prognostic  Index  (I.P.I.)  2  (stage  IV, 
elevated LDH).
Patient was treated with the immunochemotherapy 
schedule  R-CHOP-14  (Rituximab  375  mg/mq, 
Cyclophoshamide 750 mg/mq, Doxorubicin 50 mg/mq 
and Vincristin 2 mg on day 1, Prednisone 100 mg/die 
from  day  1  to  day  5,  Filgrastim  from  day  9 to  12, 
repeated  every  14  days),  with  the  addition  of 
intrathecal  prophylaxis  with  Methotrexate  at  each 
cycle. Blood chemical tests performed after 4 courses
showed  a  normalization  of  bilirubin  levels  (total 
bilirubin  0.6  mg/dl)  and  the  CT  scan  revealed  a
Figure 1. 
18F-FDG PET/CT showed increased glucose metabolism in a larger lesion in the head of pancreas (Figure 1A), as well as in one 
more smaller area in the tail of the pancreas (pointed by the arrow) and in one lymph node in the hepato-gastric ligament (Figure 1B).  Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
Figure 2. A) Endoscopic ultrasound (EUS) of the pancreatic lesion; B) hematoxylin and eosin staining of pancreatic bioptic specimen; C)
CD20 immunostaining; D) BCL-6 immunostaining.
volumetric reduction of the larger pancreatic mass (3.5 
x  2.9  cm).  Considering  the  partial  response,  the 
treatment was intensified with a 3 courses multiagent 
immunochemotherapy  Ri-MiCMA  (Rituximab  375 
mg/mq on day 1, Mitoxantrone 10 mg/mq on day 1, 
Carboplatin  100  mg/mq  from  day  1  to  day  4, 
Cytarabine 2 g/mq on day 5, Methylprednisolone 750 
mg from day 1 to 5, repeated every 21 - 28 days), with 
collection of peripheral CD34+ stem cell and followed 
by  autologous  stem  cell  transplantation.  The 
achievement of a complete remission was documented 
by a 
18F-FDG PET/CT scan performed at the end of the 
treatment.  After  almost  5  years  of  follow-up,  the 
patient is in complete remission and in good general 
condition.
Discussion. PPL is an extremely rare disease occurring 
in  pancreas,  with  or  without  the  involvement  of 
peripancreatic lymph nodes, and accounts for less than 
1% of extra-nodal malignant lymphomas and 0,5% of 
cases  of  pancreatic  masses.
1 Diagnostic  criteria  by 
Dawson  et  al.
2 include:  1- neither  superficial 
lymphoadenopathy  nor  enlargement  of  mediastinal 
lymph nodes; 2- a normal leukocyte count in peripheral 
blood; 3- main mass in the pancreas with lymph-nodal 
involvement confined to the peripancreatic region; 4-
no  hepatic  or  splenic  involvement.  The  clinical 
manifestations  and  imaging  results  of  PPL  resemble 
other pancreatic cancers, such as adenocarcinoma, but 
unlike  this,  PPL  are  potentially  treatable  even  if 
diagnosed  at  an  advanced  stage.  The  presenting 
symptoms  and  signs  include  epigastric  pain,  weight 
loss and jaundice, while other systemic symptoms such 
as fever, chills and night sweats are uncommon. PPL 
shows  a  strong  male  predominance  (male  to  female 
ratio  of  7:1),  with  median  age  of  55  years  ranging 
between 35 and 75.
1
So  far  less  than  two  hundred  cases  have  been 
described in literature consisting mainly in case reports 
or small case series.
3 The etiology is unknown and no 
association  have  been  described  with  common  viral 
agents  involved  in  the  development  of  malignant
lymphoma.  Familial  cases  of  PPL  have  been 
described.
4
Diabetes Mellitus has been reported as presenting 
symptom associated to PPL, related to the lymphoma 
infiltration  of  pancreatic  tissue  and  the  following 
exocrine and endocrine insufficiency, with spontaneous 
recovery of pancreatic function after treatment-induced 
lymphoma remission.
5,6Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
This patient suffered from Diabetes Mellitus from 1 
year  of  age,  which  was  initially  defined  as  Type  1 
Diabetes  Mellitus,  because  it  was  the  most  likely 
diagnosis according to age and presentation almost 2 
decades  ago.  Following  the  diagnosis  of  PPL, 
considering  the  intriguing  hypothesis  of  association 
between  extranodal  lymphoma  and  organ-target 
autoimmune  disease,  as  observed  for  other  types  of 
lymphoma,  the  diagnosis  of Diabetes  Mellitus  was 
revised according to immunological and genetic tests. 
Immunological  assays  including  anti-islet-cell,  anti-
GAD65, and anti-insulin autoantibodies were negative. 
Since  patient  was  obese, had  constant insulin  needs, 
and  had  a  familiar  history  of  diabetes  mellitus  and 
glucose intolerance, the diagnosis of MODY was taken 
in  consideration.  Notably,  genetic  analysis  of 
glucokinase  (GCK)  and  hepatocyte  nuclear  factor-1 
alpha (HNF1A) genes, whose mutations are the most 
common  cause  of  MODY  accounting  for 
approximately 70% of cases, was performed using a 
previously described procedure.
7 Direct sequencing of 
HNF1A  gene  resulted  in  the  identification  of  a 
missense mutation p.G31D in exon 1 caused by a G>A 
transition at nucleotide 92 resulting in the substitution 
of glycine with aspartic acid at codon 31 allowing the 
redefinition of the initial diagnosis as MODY3.
8
MODY refers to any of several hereditary forms of 
diabetes that are defined at the molecular genetics level 
by  mutations  in  different  genes  accounting  for  an 
estimated  1–2%  of  diabetes  in  Europe.  These 
monogenic  forms  are  characterized  by  early  onset 
(usually  before  25  years  of  age  and  frequently  in 
childhood or adolescence), autosomal dominant mode 
of inheritance and a primary defect in pancreatic beta 
cell function.
9 Heterozygous mutations of HNF1A gene 
are  associated  with  MODY3.
10 HNF1A  is  a 
transcription  factor    that  is  thought  to  control  a 
regulatory network important for differentiation of beta 
cells. Mutations of this gene lead to reduced beta cell 
mass  or  impaired  function.  In  experimental  models, 
HNF1A  deficiency  led  to  impaired  large-T-antigen-
induced  growth  and  oncogenesis  in  beta  cells  and 
enhanced proliferation in hepatocytes.
11
An association between a benign proliferation (such 
as liver adenomyomatosis) and MODY3 was reported, 
probably  based  on  the  involvement  of  a  biallelic 
inactivation of HNF1A in hepatic adenomas occuring 
either by double somatic events or in association with a 
germ  line  HNF1A mutation.  These  results  have 
stressed that HNF1A associated with MODY3 met the 
genetic criteria of a classical tumor suppressor gene.
12
Diabetes  Mellitus  has  been  associated  to  a 
moderately increased risk of non-Hodgkin lymphoma 
as well as other malignancies, including endometrial, 
ovarian, breast, gallbladder, liver, colon and pancreatic 
cancer,  probably  related  an  altered  immune  function 
and  a  relatively  immunodeficient  state observed  in 
diabetic  patients.
13 No  reports  have  been  so  far 
published  about  the  involvement  of  HNF1A in 
lymphomagenesis.  Unfortunately  we  had  not  enough 
bioptic material to study acquired double-hit mutations 
of  HNF1A on  pancreatic  lymphoma.  Nevertheless, 
since both conditions of MODY3 and PPL are quite 
uncommon, in particular considering the young age of 
the  patient, their interesting association  could not be 
casual  but  be  related  to  a  possible  link  involving 
HNF1A mutations,  primary  pancreatic  beta  cell 
dysfunction,  diabetes  mellitus  and  lymphoma 
development. We thought that this case is worth being 
reported  and  further  investigation  of  this  issue  are 
warranted.
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